Doxorubicin Loading in Peptide-Based Hydrogels Enables Sustained Elution and Controlled Chemotherapy Depot Performance

Detailed review of doxorubicin encapsulation in supramolecular peptide hydrogels, examining cross-beta assembly, depot release kinetics, and reduced toxicity.

EXECUTIVE SUMMARY

Key Scientific Takeaways

Essential pharmacological findings, binding kinetics, selectivity windows, and phenotypic outcomes

  • 1
    The planar anthraquinone core of the aglycone moiety participates in extensive pi-pi stacking interactions with aromatic side chains, including phenylalanine, tyrosine, and tryptophan residues within the peptide backbone [1][4].
  • 2
    Gelation kinetics proceed to completion within 20 to 40 minutes following ionic reconstitution, resulting in solid-like viscoelastic networks where the storage modulus G' exceeds the loss modulus G'' by approximately.
  • 3
    Elution kinetics of doxorubicin from supramolecular peptide hydrogels deviate markedly from classical Fickian diffusion [2][3].
  • 4
    This prolonged enzymatic stalling causes replication fork collapse, driving downstream phosphorylation of histone H2AX at Ser139 (forming gamma-H2AX foci) and subsequent activation of initiator caspase-9 and executioner caspase-3 [7][8].
  • 5
    The therapeutic window of doxorubicin is historically constrained by cumulative, irreversible dilated cardiomyopathy mediated by mitochondrial reactive oxygen species and Topoisomerase IIbeta degradation within post-mitotic cardiomyocytes [2][5].
Check the Doxorubicin (Adriamycin) Hydrochloride product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
EXTRACELLULAR MEMBRANE CYTOPLASM NUCLEUS MOA PATHWAY — Doxorubicin (Adriamycin) P=Phospho | ->=Activate | -|=Inhibit Doxorubicin Depot pKa 8.2 Loading 0.44 MMP-2/9 Free DOX ROS p38 MAPK P TOP2A ATM/ATR P CASP-3 DNA DSB / γ-H2AX p53 P Apoptosis
Proposed Mechanism of Action and Downstream Signaling Pathway Cascade of Doxorubicin (Adriamycin) Released from Peptide Hydrogel Depots.

A detailed cellular and molecular pathway schematic displaying: (1) Extracellular matrix showing peptide cross-beta nanofiber hydrogel depot eluting doxorubicin in response to low pH and matrix metalloproteinases; (2) Cellular internalization via passive diffusion and endocytic uptake; (3) Nuclear trans-localization and intercalation into genomic DNA; (4) Topoisomerase IIalpha complex trapping, double-strand break induction marked by gamma-H2AX phosphorylation; and (5) Activation of the intrinsic apoptotic cascade via cytochrome c release and caspase-9/3 cleavage.

Supramolecular Peptide Hydrogel Architecture and Non-Covalent Doxorubicin Entrapment

Self-assembling peptide networks represent an effective platform for localizing anthracycline delivery directly within neoplastic tissue beds [1]. Oligopeptides functionalized with repeating hydrophobic and hydrophilic motifs—such as alternating ionic-complementary sequences or N-terminally protected aromatic sequences such as fluorenylmethoxycarbonyl diphenylalanine—undergo spontaneous hierarchical organization [2]. Upon exposure to physiological ionic strength, these molecules undergo an order-disorder transition, moving from unstructured random coils into cross-beta-sheet fibrils [1][3]. The lateral bundling of these fibrils forms an entangled three-dimensional mesh possessing shear-thinning and rapid thixotropic recovery [4].

Non-covalent loading of doxorubicin hydrochloride relies on dual thermodynamic drivers. The planar anthraquinone core of the aglycone moiety participates in extensive pi-pi stacking interactions with aromatic side chains, including phenylalanine, tyrosine, and tryptophan residues within the peptide backbone [1][4]. Simultaneously, the protonated daunosamine amino group, possessing a pKa of 8.2, engages in electrostatic salt-bridge coordination with deprotonated carboxylates from aspartic acid or glutamic acid residues at neutral pH [2][3]. This dual interaction mechanism yields drug loading contents as high as 0.440 without premature macroscopic precipitation or syneresis over 10 days of equilibration [1]. Entrapment efficiencies regularly exceed 88% to 95% at pH 7.4 [2]. As summarized in Table 1, supramolecular peptide hydrogel matrices display distinct mechanical parameters, loading profiles, and release mechanisms compared to synthetic copolymer hydrogels and liposomal standards, establishing specific rheological and pharmacological profiles for local oncology interventions [1][2].

Hydrodynamic Swelling, Network Rheology, and Mechanical Stabilization

The macroscopic integrity and handling properties of doxorubicin-loaded peptide hydrogels depend on oscillatory rheological dynamics [1]. Gelation kinetics proceed to completion within 20 to 40 minutes following ionic reconstitution, resulting in solid-like viscoelastic networks where the storage modulus G' exceeds the loss modulus G'' by approximately one order of magnitude [1][5]. Formulations designed for peritumoral or post-resection surgical cavity administration maintain an equilibrium G' within the target range of 1 kPa to 10 kPa [2][5]. This stiffness prevents mechanical displacement under physiological shear stress while preserving high network hydration exceeding 95% water content [1][2].

Hydrogel swelling behaviour directly dictates matrix porosity and initial solute flux. In aqueous buffers containing 150 mM NaCl, osmotic hydration forces promote equilibrium water uptake ratios between 1.5 and 2.2 times the initial dry weight [3]. In unoptimized matrices, such swelling can induce a rapid burst release, liberating up to 80% of small hydrophilic therapeutics within 5 days [2][3]. In contrast, incorporating secondary supramolecular coordination strategies, such as physical crosslinking through oligomeric counterions or hybrid peptide-polysaccharide composites, restricts early macroscopic mesh dilation [2][3]. The resulting nanofibrillar pore architecture maintains an average mesh diameter between 5 nm and 25 nm, effectively trapping doxorubicin assemblies within the fibrillar crosslinks [1][5]. Consequently, the hydrogel depot demonstrates sustained retention without premature matrix dissolution under continuous fluid shear, preserving drug depot functionality over extended timeframes [2][5].

Release Kinetics, Hydrolytic Stability, and Microenvironment-Triggered Elution

Elution kinetics of doxorubicin from supramolecular peptide hydrogels deviate markedly from classical Fickian diffusion [2][3]. When assessed across dialysis membranes under sink conditions in phosphate-buffered saline containing 0.1% polysorbate 20, the elution profile exhibits anomalous non-Fickian transport governed by combined surface diffusion and slow peptide matrix relaxation [1][3]. Native peptide hydrogels restrict drug release to 16% to 28% over initial multi-day incubations, avoiding the toxic systemic bolus effect common to conventional intravenous administration [1][3]. Elution data correlate accurately with the Korsmeyer-Peppas power law model, displaying release exponents (n) between 0.60 and 0.78, which denotes mixed diffusion-erosion mass transport [2][3].

Triggered release mechanisms exploit specific biochemical abnormalities found within the tumor microenvironment [6]. In the acidic milieu of hypoxic solid malignancies, characterized by extracellular pH values between 5.5 and 6.5, the carboxylate side chains of matrix aspartate and glutamate residues undergo protonation [2][6]. This neutralizes the electrostatic attractions stabilizing the protonated daunosamine sugar, accelerating drug release up to 2.5-fold relative to neutral physiological conditions [3][6]. Orthotopic osteosarcoma models, including K12 and K7M2-WT, confirm this responsive degradation behavior, showing fluidic matrix transitions and elevated localized anthracycline release under acidic pH or local thermal cues [6]. Furthermore, the incorporation of target cleavable sequences such as Pro-Ala-Ala-Leu-Val-Ala renders the nanofibrils susceptible to matrix metalloproteinases MMP-2 and MMP-9, causing controlled matrix cleavage and sustained, zero-order release profiles lasting 14 to 28 days [7].

Topoisomerase IIalpha Poisoning and Double-Strand Break Induction Under Depot Exposure

Continuous release of doxorubicin from peptide hydrogel depots sustains steady-state intratumoral drug concentrations sufficient to poison Topoisomerase IIalpha [7][8]. In classic systemic delivery, rapid peak clearance limits the duration of ternary Topoisomerase II-doxorubicin-DNA covalent complexes. In contrast, steady nanomolar elution promotes persistent enzyme-mediated double-strand DNA scission [7][8]. This prolonged enzymatic stalling causes replication fork collapse, driving downstream phosphorylation of histone H2AX at Ser139 (forming gamma-H2AX foci) and subsequent activation of initiator caspase-9 and executioner caspase-3 [7][8].

In vitro cytotoxicity evaluations using triple-negative breast cancer MDA-MB-231 cells demonstrate that doxorubicin liberated from cleavable peptomer-linked hydrogel conjugates maintains therapeutic activity, showing a 3-day IC50 of 0.51 μM, equivalent to the free clinical agent [7]. In parallel studies, doxorubicin-loaded peptide nanogels and hydrogels reduce breast carcinoma cell viability to 49%–57% at 24 hours and 7%–25% at 72 hours, whereas carrier-only controls retain cell viability above 95% [1]. Continuous local diffusion from injectable matrices also suppresses the growth of B16-F10 melanoma and 4T1 murine mammary carcinoma [3][8]. The localized depot sustains a continuous chemical gradient that penetrates high interstitial fluid pressure zones within dense tumor stroma, inducing extensive apoptosis across deep tumor parenchyma without requiring high systemic peak concentrations [7][8].

Pharmacokinetic Alterations and Attenuation of Dose-Limiting Cardiotoxicity

The therapeutic window of doxorubicin is historically constrained by cumulative, irreversible dilated cardiomyopathy mediated by mitochondrial reactive oxygen species and Topoisomerase IIbeta degradation within post-mitotic cardiomyocytes [2][5]. Local matrix implantation significantly alters systemic anthracycline pharmacokinetics, attenuating off-target cardiac tissue accumulation [2][8]. Following local hydrogel placement adjacent to primary tumor sites or surgical resection margins, peak plasma concentration (Cmax) drops by more than 75% compared to equivalent doses administered by intravenous bolus injection [2][5].

Systemic exposure parameters confirm that the area under the plasma concentration-time curve (AUC0-inf) remains within safe physiological thresholds, preventing cardiac sequestration of doxorubicin and its cardiotoxic secondary alcohol metabolite, doxorubicinol [2][6]. In murine models, animals receiving local hydrogel depots show normal baseline levels of serum troponin-I and B-type natriuretic peptide, in contrast to the substantial elevations caused by free drug regimens [5][6]. Histopathological evaluation confirms intact myocardial myofibrillar architecture without cytoplasmic vacuolization or interstitial fibrosis [2][5]. Hematological counts, including white blood cells, red blood cells, and platelets, alongside serum alanine aminotransferase and aspartate aminotransferase, remain stable, demonstrating preserved bone marrow and hepatic function [5]. Peptide-based hydrogels thus improve the safety profile of doxorubicin by transforming a systemic toxin into a well-tolerated, localized therapeutic depot [2][5].

Table 1. Comparative Pharmacological, Binding Affinity, and Selectivity Benchmark of Doxorubicin (Adriamycin)

Formulation / Delivery MatrixDrug Loading Content (DLC)Entrapment Efficiency (%)Elastic Modulus (G', kPa)Predominant Release MechanismSystemic Cmax & Toxicity Risk
Supramolecular Peptide Hydrogel0.14 - 0.4485% - 95%1.0 - 10.0Anomalous non-Fickian diffusion + enzyme/pH matrix erosionMinimal systemic Cmax; lowest cardiotoxicity
PEG-PLGA Copolymer Hydrogel0.05 - 0.1560% - 78%0.5 - 3.5Hydrolytic ester degradation + bulk diffusionModerate systemic leak; intermediate cardiotoxicity
Liposomal Doxorubicin (Doxil standard)0.10 - 0.12>90%N/A (Colloidal suspension)Circulatory circulation + passive EPR extravasationLow free Cmax; risk of palmar-plantar erythrodysesthesia
Free Doxorubicin HydrochlorideN/A (Small molecule)N/AN/AImmediate systemic bolus distributionHigh systemic Cmax; severe dose-limiting cardiotoxicity

Note: Comparison of supramolecular peptide hydrogel depots against synthetic copolymer hydrogels, commercial liposomes, and unformulated doxorubicin hydrochloride. Data compiled across empirical literature standards.

PRECLINICAL INVESTIGATION Q&A

Frequently Asked Questions

Critical scientific answers for assay design, target selectivity, cell model selection, and dosing regimens

What is the significance of Supramolecular Peptide Hydrogel Architecture and Non-Covalent Doxorubicin Entrapment?Mechanism of Action

Self-assembling peptide networks represent an effective platform for localizing anthracycline delivery directly within neoplastic tissue beds [1]. Oligopeptides functionalized with repeating hydrophobic and hydrophilic motifs—such.

What is the significance of Hydrodynamic Swelling, Network Rheology, and Mechanical Stabilization?Pharmacological Potency

The macroscopic integrity and handling properties of doxorubicin-loaded peptide hydrogels depend on oscillatory rheological dynamics [1]. Gelation kinetics proceed to completion within 20 to 40.

References

  1. [1]. Gallo E, et al. International Journal of Nanomedicine. 2021;Volume 16:1617-1630. [IF: 7.033]
  2. [2] PMCID: PMC12293504. [IF: 4.4]
  3. [3]. Seo HS, et al. Biomaterials Research. 2024;28. [IF: 9.6]
  4. [4]. Xu L, et al. Theranostics. 2020;10(18):8162-8178. [IF: 11.556]
  5. [8]. Jin R, et al. Journal of Nanobiotechnology. 2019;17(1). [IF: 6.518]
  6. [5]. D'Anna G, et al. International Journal of Nanomedicine. 2025;Volume 20:14787-14822. [IF: 6.5]
  7. [6]. Watkins CM, et al. Advanced Healthcare Materials. 2025;15(11). [IF: 9.6]
  8. [7]. Rothe R, et al. Advanced Healthcare Materials. 2024;13(27). [IF: 9.6]